RT Journal Article
SR Electronic
T1 Machine Learning Based Prediction of COVID-19 Mortality Suggests Repositioning of Anticancer Drug for Treating Severe Cases
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.11.21266048
DO 10.1101/2021.11.11.21266048
A1 Thomas Linden
A1 Frank Hanses
A1 Daniel Domingo-Fernández
A1 Lauren Nicole DeLong
A1 Alpha Tom Kodamullil
A1 Jochen Schneider
A1 Maria J.G.T. Vehreschild
A1 Julia Lanznaster
A1 Maria Madeleine Ruethrich
A1 Stefan Borgmann
A1 Martin Hower
A1 Kai Wille
A1 Thorsten Feldt
A1 Siegbert Rieg
A1 Bernd Hertenstein
A1 Christoph Wyen
A1 Christoph Roemmele
A1 Jörg Janne Vehreschild
A1 Carolin E. M. Jakob
A1 Melanie Stecher
A1 Maria Kuzikov
A1 Andrea Zaliani
A1 Holger Fröhlich
A1 LEOSS study group
YR 2021
UL http://medrxiv.org/content/early/2021/11/12/2021.11.11.21266048.abstract
AB Despite available vaccinations COVID-19 case numbers around the world are still growing, and effective medications against severe cases are lacking. In this work, we developed a machine learning model which predicts mortality for COVID-19 patients using data from the multi-center ‘Lean European Open Survey on SARS-CoV-2-infected patients’ (LEOSS) observational study (>100 active sites in Europe, primarily in Germany), resulting into an AUC of almost 80%. We showed that molecular mechanisms related to dementia, one of the relevant predictors in our model, intersect with those associated to COVID-19. Most notably, among these molecules was tyrosine kinase 2 (TYK2), a protein that has been patented as drug target in Alzheimer’s Disease but also genetically associated with severe COVID-19 outcomes. We experimentally verified that anti-cancer drugs Sorafenib and Regorafenib showed a clear anti-cytopathic effect in Caco2 and VERO-E6 cells and can thus be regarded as potential treatments against COVID-19. Altogether, our work demonstrates that interpretation of machine learning based risk models can point towards drug targets and new treatment options, which are strongly needed for COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work has been funded via the COPERIMOplus initiative and supported by the Fraunhofer Internal Programs under Grant No. Anti-Corona 840266. The LEOSS registry was supported by the German Centre for Infection Research (DZIF) and the Willy Robert Pitzer Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:LEOSS is registered at the German Clinical Trials Register (DRSK, S00021145) and was approved by the leading Ethics Commitee No. 20-600 "Ethikkommission des Fachbereichs Humanmedizin der Johann-Wolfgang-Goethe-Universitaet Frankfurt am Main, 60590 Frankfurt, Germany". For the anonymization procedure see (Jakob et al. 2020).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data analyzed in this study is subject to the following licenses/restrictions: Data will be available for research purposes. Data access has to be requested from https://leoss.net/ Access can be requested from https://leoss.net/registration/ https://github.com/thomasmooon/leoss-cov19 https://leoss.net/